Boston Scientific (NYSE:BSX) Price Target Raised to $125.00

Boston Scientific (NYSE:BSX) had its price target lifted by Wells Fargo & Company from $124.00 to $125.00 in a research note published on Thursday, MarketBeat.com reports. Wells Fargo & Company currently has an overweight rating on the medical equipment provider’s stock.

Other research analysts have also recently issued research reports about the company. Barclays increased their target price on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Morgan Stanley lifted their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday. Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Needham & Company LLC restated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific currently has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Trading Down 1.3%

Shares of BSX stock opened at $101.08 on Thursday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific has a 52-week low of $80.64 and a 52-week high of $109.50. The company has a market capitalization of $149.78 billion, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The business’s fifty day moving average is $101.14 and its 200 day moving average is $102.08.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the business posted $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts anticipate that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director directly owned 2,081 shares of the company’s stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 170,214 shares of company stock worth $17,548,337. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A number of hedge funds have recently made changes to their positions in the stock. Pinnacle Bancorp Inc. boosted its position in shares of Boston Scientific by 21.1% in the 3rd quarter. Pinnacle Bancorp Inc. now owns 1,632 shares of the medical equipment provider’s stock worth $159,000 after purchasing an additional 284 shares in the last quarter. MGO One Seven LLC boosted its position in shares of Boston Scientific by 22.1% in the 3rd quarter. MGO One Seven LLC now owns 20,306 shares of the medical equipment provider’s stock worth $1,982,000 after purchasing an additional 3,678 shares in the last quarter. Citizens Financial Group Inc. RI boosted its position in shares of Boston Scientific by 13.6% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 16,090 shares of the medical equipment provider’s stock worth $1,571,000 after purchasing an additional 1,930 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in shares of Boston Scientific by 679.2% in the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 9,608 shares of the medical equipment provider’s stock worth $984,000 after purchasing an additional 8,375 shares in the last quarter. Finally, Tema Etfs LLC boosted its position in shares of Boston Scientific by 148.1% in the 3rd quarter. Tema Etfs LLC now owns 42,950 shares of the medical equipment provider’s stock worth $4,193,000 after purchasing an additional 25,641 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.